

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

SUPPLEMENTAL ANNOUNCEMENT
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
AND RELEVANT RULES OF PROCEDURES

Reference is made to the announcement of CanSino Biologics Inc. (the “**Company**”) dated April 28, 2023 (the “**Announcement**”) in relation to the proposed amendments to the articles of association of the Company (the “**Articles of Association**”) and the relevant rules of procedures of the Company. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The proposed amendments to the Articles of Association and Relevant Rules of Procedures were made in light of the recent changes in the PRC regulations. The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) also proposed to make consequential amendments to the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) to reflect the recent changes in the PRC regulations. As the amended Listing Rules have not become effective and are subject to the necessary regulatory approvals, the proposed amendments to the Articles of Association and Relevant Rules of Procedures may be further updated.

As such, the Company decided to convene a general meeting and class meetings to consider and approve the proposed amendments to the Articles of Association and Relevant Rules of Procedures after the amended Listing Rules become effective. The Company will further make disclosure regarding the proposed amendments to the Articles of Association and Relevant Rules of Procedures as and when appropriate in compliance with the amended Listing Rules.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 12, 2023

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.